Robert L. Rosiello
CIK 1645041 · EVP, Corp Dev & Strategy · last filed 2026-07-10
Robert L. Rosiello is an EVP, Corp Dev & Strategy who has filed 18 SEC Form 4 insider transactions across 5 companies since 2022. The most recent filing, for MCRB, was dated Jul 10, 2026. 10 SEC filings were submitted jointly with Bausch Health Companies Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MCRB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 400
SEATTLE, WA 98102
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MCRB | Director | — | $1.98 | — | $0 | 3 | 2026-07-10 |
| SANA | Director | — | $2.36 | — | $0 | 2 | 2026-06-05 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | — | $0.14 | — | $0 | 1 | 2024-10-04 |
| Evelo Biosciences, Inc. (EVLO) Delisted | Director | — | $0.00 | — | $0 | 2 | 2023-06-12 |
| Axcella Health Inc. (AXLA) Delisted | Director | — | $0.40 | — | $0 | 1 | 2022-11-18 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-10 | MCRB | Grant (A) | — | $0 | EDGAR |
| 2026-07-02 | MCRB | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-08-06 | MCRB | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | SANA | Grant (A) | — | $0 | EDGAR |
| 2024-10-04 | Omega Therapeutics, Inc. (OMGA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | Evelo Biosciences, Inc. (EVLO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-04-18 | Evelo Biosciences, Inc. (EVLO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-11-18 | Axcella Health Inc. (AXLA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-07 | — | Tax (F) | −14,687 | -$264.4K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.